Gabriel Holding A/S (CPH:GABR) on Thursday reported profit before tax of DKK14.2m for the first quarter of the financial year 2017/18 .
This was a 49% increase as compared with profit before tax of DKK9.5m in Q1 2016/17.
Operating profit (EBIT) for the quarter increased by 64% to DKK13.7m, as compared with DKK8.4m in Q1 2016/17.
Revenues for the quarter increased by 24% to DKK144.7m, as compared with DKK117.0m in Q1 2016/17. Reportedly, this increase in revenues is a result of growth on the main markets and in all business units.
The company provided expectations for the 2017/18 financial year and expects growth in revenues and earnings for the full year to get close to 15% in the range of 10% to 15% stated in the annual report. This is as a result of revenues and earnings realised for the quarter exceed management's expectations.
Gabriel Holding develops, manufactures, and sells furniture fabrics of pure wool and micro fibres, and related textile products. The company's product line includes fabrics for upholstered furniture, as well as for office, theatre, hospital, and hotel furniture, as well as furnishing fabrics for trains, ships, cars and buses.
(EUR1.00=DKK7.44)
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025